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Abstract 
Ghrelin is a stomach derived hormone that stimulates appetite. H2S a gaseous signaling molecule 
also produced in the stomach has been implicated in the secretion of other metabolic hormones. 
We hypothesize that H2S can directly suppress ghrelin secretion leading to a reduction in 
appetite. We tested this by treating ghrelin producing rat primary stomach culture with the H2S 
donor molecule GYY4137 or H2S synthesis inhibitor PPG. GYY4137 dose-dependently 
suppressed ghrelin secretion, while increasing cellular levels of phosphorylated AKT/Total AKT. 
Additionally, fluorescent immunocytochemistry demonstrated of that ghrelin cells co-localize 
with the H2S producing enzyme, CSE and inhibition with PPG stimulated ghrelin secretion. In 
mice, a single IP injection with GYY4137 (30mg/kg) prolonged glucose induced suppression of 
ghrelin compared to saline control. This lower level of ghrelin was accompanied by a reduction 
in feeding (P<0.05). In conclusion, our data demonstrates that H2S has a suppressive effect on 
ghrelin secretion and appetite. 
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1 
Introduction 
1.1 Metabolic Disease Impacts in Canada 
Two of the most prevalent metabolic diseases are obesity and type 2 diabetes mellitus. Obesity is 
defined as having a body mass index (BMI; height in cm/weight in kg2) of 30 or higher while 
being overweight is defined by a BMI above 25. Obesity is associated with risk factors such as 
cardiovascular disease, high blood pressure, increased plasma triglycerides, hyperglycemia, 
lower high density lipoprotein (HDL)-cholesterol and an increased risk of developing type 2 
diabetes mellitus (1). The latter is characterized by hyperglycemia and the inability for insulin to 
store glucose in peripheral tissues. Other symptoms associated type 2 diabetes mellitus are 
polydipsia, polyuria, blurred vision, fatigue, weight change and slow wound healing. Type 2 
diabetes mellitus also shares many of the same comorbidities as obesity (2). Both chronic 
conditions have been increasing in prevalence and a 2015, Statistics Canada study reported that 3 
comorbidities of obesity, heart disease, stroke and diabetes mellitus, are 3 of the top 10 leading 
causes of death for Canadians (3). The Canadian Obesity Network reported that in 2010 one in 
four adults and one in ten children in Canada were classified as obese. Not only that, but 
prevalence of this condition was increasing despite an estimated six billion dollars of the health 
care budget being used to help treat patients suffering from this disease (4). The current 
strategies used to treat obesity are proving ineffective on a national scale and thus research into 
the physiology of the digestive and endocrine systems is essential. Understanding how this 
systems function and interact will further our knowledge of metabolism allowing us to better 
understand the current health implications of metabolic diseases such as obesity. One such 
system that plays a major role in metabolic health is the gastrointestinal (GI) tract. 
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1.2 Gastrointestinal Hormones and Metabolism 
The GI tract is responsible for the breakdown and absorption of nutrients for the body to use as 
energy. This process takes place through mechanical breakdown, enzymatic cleavage, and 
microbial fermentation of nutrients until they can be absorbed through the intestinal epithelium. 
The GI tract is comprised of the oral cavity, esophagus, stomach, small intestines, large intestines 
and rectum (5). Absorption is not the only function of the GI tract. The GI tract is also lined with 
many cells capable of nutrient sensing and hormone production called enteroendocrine cells (6). 
These cells sense the composition and quantity of nutrients ingested leading to regulation in the 
release of gastrointestinal hormones. Gastrointestinal hormones regulate various metabolic 
processes such as appetite, plasma glucose levels, digestion of nutrients, gut motility, and the 
storage or utilization of energy (6).  
There is a large variety of enteroendocrine cell types found throughout the digestive system 
which have unique functions. Table 1 below is adapted from (6) and lists many of the 
enteroendocrine and pancreatic cells, where they are localized, what hormone they produce and 
secrete and the general effect of that hormone. Hormones send signals throughout the body 
which alter cells function, metabolism is one such process that is controlled by the regulation of 
multiple hormones. The hormone ghrelin can alter metabolism and stimulate appetite making it 
an important hormone to consider in metabolic diseases (6). It is the hormone of interest in this 
manuscript. 
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Table 1: Major metabolic hormones (Adapted from (6)) 
 
Cell Type Cell Localization Major hormone 
released 
Main function 
P/D1 cell/ε-cells (X/A-like cells in 
rodents) 
(P/D1 cells in human 
Stomach) 
(Epsilon cells in 
pancreas) 
Ghrelin 
• Appetite control 
• Growth hormone 
secretagogue 
• Energy balance 
β-cell Pancreas Insulin 
• Glucose, carbohydrate, 
fats, and protein uptake 
in tissues 
(metabolism/storage) 
α-cell Pancreas Glucagon 
• Conversion of glycogen 
into glucose 
• Inhibits glycolysis 
L-cell Ileum, colon GLP-1 
• Incretin effect 
• Appetite control 
• Gut motility 
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1.3 Ghrelin the “Hunger Hormone” 
Ghrelin was originally discovered as an endogenous ligand for the growth hormone secretagogue 
receptor (GHSR). This receptor starts the signaling pathway which results in the release of 
growth hormone (GH). Ghrelin was named for this pathway as “ghre” is the Proto-Indo-
European term for grow (7). While its seminal discovery linked ghrelin with growth hormone 
secretion, continued work has implicated ghrelin in appetite and energy balance. This section 
will describe the production, action and dysfunction of ghrelin in metabolic diseases as well as 
how the secretion of this hormone is controlled. 
 
1.3.1 Ghrelin Synthesis and Expression 
Ghrelin was an unknown ligand when it was discovered to bind to the growth hormone 
secretagogue receptor 1a (GHSR1a). Purification and sequencing of this peptide showed it to be 
28 amino acids in length (7). Ghrelin is expressed from the preproghrelin gene which can also 
create a 23-amino acid peptide known as obestatin (8). Ghrelin can be produced in either an acyl, 
or des-acyl form, the former having the octanoic moiety being added to the 3rd amino acid in the 
sequence, which is serine. The addition of the octanoic acid is through the enzyme ghrelin O-
acyl transferase (GOAT) which has been found to be localized in the endoplasmic reticulum 
where the peptide undergoes posttranslational modification (9,10). Acylated ghrelin is capable of 
interacting with GHSR1a and is known as the active form of ghrelin as the function of des-acyl 
ghrelin is still unknown (11). 
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Figure 1: Preproghrelin and posttranslational processing (Adapted from (12)) 
 
When discovered, ghrelin was found to be produced mainly in the stomach. The enteroendocrine 
X/A-like cells of the upper fundus synthesize ghrelin and make up approximately 20% of the 
endocrine cells in the oxyntic glands of the fundus. X/A-like cells are also expressed throughout 
much of the proximal small intestines although in lesser concentrations than the stomach (13). 
Approximately 70% of plasma ghrelin concentrations are derived from the stomach, as when it is 
removed by gastrectomy ghrelin levels drop dramatically. The remaining stomach tissue can 
compensate, given time, by creating more ghrelin-producing cells or upregulating expression of 
ghrelin production, with the gastric fundus being the most capable tissue of providing this 
compensation (14). The ghrelin producing cells within the small intestine and colon, present in 
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the crypts and villi, are predominantly open type cells in contrast to the closed type cells present 
in the stomach tissue. Cells open to the luminal contents are likely nutrient sensing and have a 
separate pathway of regulation compared to the closed type cells (15). The endocrine pancreas 
also contains ghrelin producing ε-cells and the glucagon secreting α-cells can produce ghrelin as 
well (16). The ghrelin producing cells are in greater abundance in the pancreas during gestational 
development and decline postnatally, suggesting a role in development of the embryonic 
pancreas (17). Another well documented location of ghrelin expression is within the central 
nervous system. The hypothalamus, cerebral cortex and brainstem all contain ghrelin producing 
cells, which has been well documented using immunofluorescent techniques in rats and 
transgenic mice (18,19).  
 
1.3.2 Functions of Ghrelin 
As mentioned previously, ghrelin is a hormone that helps regulate appetite and energy 
metabolism. Most of this hormone is produced in the stomach and many of the effects it has 
relate to energy metabolism. However, it was originally discovered for activation of a receptor in 
the central nervous system, and expression of receptors in which ghrelin can bind are not 
exclusive to the digestive system. This section will discuss the various functions of ghrelin in the 
body with a focus on appetite and energy balance. 
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1.3.2.1 Growth Hormone Release 
As mentioned previously, ghrelin was discovered as the ligand that binds to GHSR1a. This 
knowledge has been used to confirm the function of ghrelin in GH release in humans (7,20). 
Acyl-ghrelin is the only form of ghrelin that binds to this receptor on the anterior pituitary gland 
and stimulates a greater secretion of GH than growth hormone releasing hormone (GHRH) alone 
(11). Both ghrelin and GHRH target separate G-coupled receptors in separate structures in the 
brain. Ghrelin binds to GHSR1a in the arcuate nucleus of the hypothalamus, whereas GHRH 
binds to growth hormone releasing hormone receptor in the anterior pituitary gland (21). 
Treatment with either hormone will increase GH secretion but treatment with both hormones 
together provided a synergistic increase to GH secretion (22). GH is involved with many 
anabolic processes, primary by signaling the release of insulin-like growth factor 1 (IGF-1) from 
the liver. GH also stimulates gluconeogenesis in the liver and inhibits the uptake of glucose in 
peripheral adipose tissue while promoting glucose storage in skeletal muscles (23). Together 
these demonstrate the importance of ghrelin in the storage and utilization of energy through GH 
regulation. 
 
1.3.2.2 Energy Mobilization and Storage 
The indirect increase in secretion of GH and IGF-1 is not the only way in which ghrelin can 
regulate energy balance in the body. As ghrelin secretion is primarily controlled based upon 
energy state, it is not surprising that it has multiple effects on the availability of macronutrients. 
Ghrelin has an important role in regulating plasma glucose levels as it was discovered that 
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mRNA for GHSR was present in pancreatic cells (24). Insulin secretion from the pancreas helps 
manage plasma glucose. Ghrelin suppresses insulin secretion and reduces the glucose induced 
insulin response (25,26). This was later confirmed in a study showing that the suppression can be 
blocked using GHSR1a antagonists (27). This suppressive effect on insulin is activated through 
voltage dependent K+ channels (28). Experiments isolating and examining the pancreatic artery 
and vein in mice show a greater level of ghrelin in the pancreatic vein and decreased suppression 
in isolates from ghrelin knockout (KO) mice (29). This suggests that pancreatic production of 
ghrelin is also actively regulating hormone secretion from the pancreas. Ghrelin may also have 
an indirect effect on insulin secretion by regulating the secretion of another pancreatic hormone 
which acts to raise blood glucose levels in a fasted state. Ghrelin directly stimulates glucagon 
secretion from α-cells of the pancreas (30). In addition to regulating insulin secretion, ghrelin has 
also been shown recently to have a role in reducing insulin sensitivity in peripheral tissues (31). 
Beyond its roles in insulin regulation, ghrelin also has roles in promoting gluconeogenesis in 
hepatic cells, as well as promoting storage of glucose in skeletal muscle and adipose tissue likely 
through upregulation of GLUT4 transporters in these tissues (32). This increased uptake of 
glucose into adipocytes may predispose fat accumulation. Indeed, treatments with ghrelin have 
also shown an increase in adiposity while appetite and food consumption between groups 
remained the same (33). Another study involving constant ghrelin infusion showed increased 
free fatty acids in subjects receiving the ghrelin treatment. However this may be the result of 
growth hormones effect on lipolysis in a fasted state (34,35) While both ghrelin and ghrelin 
receptor KO mice exhibit normal appetite and body weight on a chow diet, these KO animals are 
resistant to high fat diet induced obesity suggesting that ghrelin and ghrelin signaling are 
essential to the formation of adipose tissues (36,37). 
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1.3.2.3 Appetite Stimulation 
Ghrelin has many functions in helping us store the nutrients we ingest, but ghrelin levels are 
highest in a fasted state and there is a relationship between ghrelin and appetite. Initial studies 
showed a dose dependent stimulation of appetite when ghrelin was injected 
intracerebroventricularly in rodents (33). The orexigenic effect ghrelin has was further examined 
by Wang et. al  where they looked into how intraperitoneal (IP) injections of ghrelin dose-
dependently increased appetite in mice (38). The function of neuropeptide Y (NPY)-releasing 
neurons in the arcuate nucleus (ARC) in stimulating appetite and increasing feeding responses is 
well understood (39). The group examined how increased ghrelin would affect activation of 
these neurons in the ARC by measuring fos activation via immunohistochemistry. They found 
that the IP injections of ghrelin showed activation of fos in cells and that 90% of those cells 
began expressing NPY mRNA in response to treatment. This confirmed that the appetite-
stimulating effect of ghrelin is signalled through hypothalamic NPY-expressing neurons (38). As 
most ghrelin is produced peripherally, an interesting study showed that peripheral ghrelin can act 
in the central nervous system by crossing the blood brain barrier (BBB) using transporters (40). 
The rate at which peripheral ghrelin is transported across this barrier appears to be dependent 
upon nutrient status (41). Due to the limited ability for ghrelin to cross the BBB it is important 
that it can signal in the brain through other means. Ghrelin receptors can be found on the afferent 
portions of the vagus nerve. This afferent signalling is believed to stimulate appetite as vagotomy 
and pharmacological inhibition of the vagus nerve were shown to block the effects of ghrelin 
(42). Immunohistochemical stains of the ARC detecting fos and NPY expression confirmed that 
the orexigenic stimulation described previously can also be signaled through the vagus nerve 
(43). In contrast another group examined the effects of IP-injected ghrelin in rats having 
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undergone the most selective form of vagotomy and found the appetite stimulation was similar to 
the control group. (44). This maintained stimulation could be due to the ability for peripheral 
plasma ghrelin to cross the BBB causing the orexigenic effect of ghrelin through increased 
expression of NPY in the ARC. Ghrelin signalling through the vagus nerve has also been shown 
to inhibit the satiety-promoting effects of other gut hormones (45).  
Beyond regulating appetite, ghrelin can stimulate food reward systems as well, which is 
reviewed in depth by Perelló et al. (46) . Of note is a study showing that reward-based feeding 
depended on the presence of the GHSR and GOAT enzyme using KO-mice. GOAT KO-mice 
showed decreased desire for high fat diet food, confirming that acyl ghrelin production is 
required to stimulate reward based feeding (47).  
 
1.3.2.4 Other Systems Affected by Ghrelin 
The expression of ghrelin receptors is also found in a variety of tissues and so here we will 
briefly discuss other roles ghrelin may play in the body. Ghrelin has other roles in the 
gastrointestinal tract, such as increasing gastric emptying which may be mediated through 
increased gut motility by binding to GHSR1a activating pathways in the enteric nervous system 
(46,47). Other metabolic hormones being regulated by ghrelin have been discussed and changes 
to their secretion could be involved in these modifications in gut motility (6). The effects are 
thought to be important in ghrelin’s role of preparing the body for its next meal. In the 
cardiovascular system ghrelin has a role in vasodilation signaled through nitric oxide (50,51). It 
is also cardioprotective during ischemia and reperfusion by reducing apoptosis caused by 
reactive oxygen species and inflammation (52). Within the central nervous system, specifically 
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the hippocampus, ghrelin has been seen to have a neuroprotective effect on cells resulting in 
increased memory and memory retention. This is supported by the observation that ghrelin KO 
mice have memory deficits that can be reversed upon ghrelin administration (53). This 
promotion of neurogenesis could be through indirect effects such as the release of growth 
hormone or IGF-1 as both have been shown to produce similar effects (54,55). It is currently 
thought that exercise is an important lifestyle change that can prevent or slow the progression of 
Alzheimer’s disease and other forms of dementia. It is suggested that an increase in ghrelin 
levels may mediate some of the beneficial effect of exercise on brain function (56). In the 
reproductive system ghrelin has shown an inhibitory effect on gonadotropin releasing hormone, 
which would decrease the secretion of follicle stimulating hormone and luteinizing hormone 
(57).  
 
 
 
 
 
 
 
 
 
12 
Table 2: Summary of the effects of ghrelin 
 
Function Effect 
Growth Hormone Release Increased 
Insulin Secretion Decreased 
Gluconeogenesis Increased 
Adipose Tissue Formation Increased 
Appetite Increased 
Gastric Emptying Increased 
Vasodilation Increased 
Memory Formation Increased 
 
1.3.3 Ghrelin Levels in Metabolic Diseases 
In the previous section, the function of ghrelin in the body was discussed. It is shown that ghrelin 
is primarily involved in regulating appetite, energy availability and metabolism. When a 
metabolic disease is present, one or more of these processes is altered along with the secretion of 
metabolic hormones. Therefore, understanding ghrelin regulation is important as it is sometimes 
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unclear if the change in ghrelin secretion is the cause or the result of the disease state and 
whether manipulating ghrelin levels would prove beneficial to patients. 
 
1.3.3.1 Ghrelin in Obesity 
A concern for many in society today is the continuous rise in obesity rates. As weight gain is 
normally the result of a higher intake in calories than those used, most treatments for obesity 
target diet and exercise with varied effect. As this is a growing health complication, an 
understanding of physiological mechanisms that control energy balance is important to develop 
new effective treatments for this disease. 
Ghrelin is a regulator of appetite and energy metabolism and both basal and fasting plasma 
ghrelin levels are altered during obesity (58,59). One might expect that since ghrelin promotes 
appetite and energy partitioning to adipocytes, that ghrelin levels would be elevated in an obese 
state (33). However, the opposite is true, as pre-meal ghrelin levels are generally lower in obese 
individuals and negatively correlate with an individual’s BMI (59). Lower ghrelin levels may be 
related to the increased energy availability in an obese state as there is increased adipose tissue 
providing a higher quantity of fatty acids for energy utilization. Ghrelin is involved with 
stimulating appetite and managing energy balance and the chronic surplus of available energy in 
obese individuals may be causing these decreased ghrelin levels. While ghrelin levels may be 
lower throughout the day, there appears to be a dysfunction in the post-meal percentage drop in 
ghrelin secretion in humans (58,60). This impaired drop in ghrelin may be partially responsible 
for the reports of increased appetite in obese individuals. Another suggestion is altered acylation 
of ghrelin in obese and diabetic individuals (61). Despite lower levels of total ghrelin there is an 
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increased ratio of acylated ghrelin to unacylated ghrelin which could be altering the hormones 
effect on appetite in obese individuals (61). 
1.3.3.2 Ghrelin and Insulin Resistance 
Type 2 diabetes mellitus is a comorbidity of obesity and is characterized by hyperglycemia, 
hyperinsulinemia and insulin resistance (62). Ghrelin has a suppressive effect on insulin and 
likewise insulin has been shown to have a suppressive effect on ghrelin secretion (63). Prior to 
this, studies have been conducted showing that ghrelin concentrations are not only decreased in 
obese individuals, but also suppressed further in individuals with insulin resistance (64). This 
suggests that ghrelin secretion could be further impaired in obese individuals who are also 
insulin resistant, as the pancreas increases insulin secretion to overcome the insulin insensitivity 
associated with type 2 diabetes mellitus. With these alterations in ghrelin in different diseased 
states, it is important to examine different regulators of the hormone to determine if restoring 
ghrelin secretion to normal levels can help reverse the diseased state. 
 
1.3.4 Ghrelin Regulation 
As ghrelin secretion can be altered in metabolic diseases, understanding how it is normally 
regulated is important. The location of ghrelin producing cells and how both ghrelin production 
and secretion are managed is essential to the study of this hormone. The next section will now 
expand upon those concepts by discussing the stimuli that signal these cells. 
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1.3.4.1 The Effect of Fasting and Feeding on Ghrelin Secretion 
It is well established that plasma ghrelin levels rise in a fasted state and fall post meal. This has 
been shown in both rats and humans since ghrelin was first found to play a role in appetite 
regulation (33). The documentation of ghrelin levels during a circadian rhythm was done later by 
Cummings et. al which showed fluctuations in plasma ghrelin over the course of meal times with 
peaks right before each meal and troughs immediately after (65). An interesting finding has been 
that ghrelin regulation has been shown to maintain rising and falling patterns around expected 
mealtimes during a 24 hour fast (66). The fasted state is the primary reason why ghrelin 
increases prior to meals although this shows that it is not the sole regulator of ghrelin secretion. 
Ghrelin may promotes gluconeogenesis in a fasted state or the storage of macronutrients post-
meal (32,67). All these functions support the necessity for a rise in ghrelin during a fasted state 
and the decline in ghrelin post meal.  
 
Figure 2: Plasma ghrelin fluctuations during a 24 hour cycle (65) 
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1.3.4.2 Hormones Regulation of Ghrelin 
In response to meals, the secretion of several hormones is modulated, which could in turn 
regulate the secretion of ghrelin. Insulin is a hormone that is secreted post-meal from the 
pancreas and aids in storing and managing the large amount of glucose that has just entered the 
circulatory system. As such it has an inverse secretion pattern with ghrelin post-meal. Insulin has 
been shown to have a rapid inhibitory effect on ghrelin levels when injected into peripheral 
circulation (68). This suppressive effect was confirmed in cell culture, helping to discover the 
cellular mechanism that insulin triggers to suppress ghrelin secretion (63). Phosphoinositide 3-
kinase (PI3K) and protein kinase B (AKT) are two intracellular kinases known to be involved 
with many cell signaling pathways and have increased activity during the suppression of ghrelin 
secretion by insulin (63,69). Glucagon-like peptide-1 (GLP-1) an incretin hormone with 
functions such as satiety and a glucose-dependent increase in insulin secretion has also been 
shown to inhibit ghrelin secretion (70). Although this was initially thought to occur through an 
increase in insulin secretion, studies using a GLP-1 receptor agonist have shown a suppression of 
ghrelin in the absence of increased insulin levels potentially suggested that GLP-1 suppresses 
ghrelin via an independent pathway (71,72). Glucagon is another hormone involved with glucose 
homeostasis by promoting gluconeogenesis in the liver. This hormone was initially believed to 
suppress ghrelin in human studies (73). However, further investigation using ghrelin-secreting  
rat stomach primary culture confirmed glucagon’s direct stimulatory effect on ghrelin secretion 
(74). 
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1.3.4.3 Nervous Systems role in Ghrelin Secretion 
The nervous system is responsible for receiving stimuli and sending signals throughout the body. 
The autonomic branch of the nervous system controls involuntary processes of the body such as 
vascular tension, inflammation and digestion. Norepinephrine is a neurotransmitter of the 
sympathetic nervous system that plays a role in ghrelin regulation. Norepinephrine is involved 
with our fight or flight responses and aids in mobilizing glucose to provide our body the energy 
it needs to allow us to survive stressful experiences. A way in which Norepinephrine raises 
plasma glucose is by increasing ghrelin secretion (63). Norepinephrine increases the expression 
of cyclic adenosine monophosphate (cAMP), protein kinase A (PKA) and the secretion of 
ghrelin from rat stomach primary culture (63). This pathways importance was examined by the 
use atenolol and H89 which are inhibitors for β1-adrenergic receptors and PKA respectively. The 
use of either of the inhibitors removed the increase in ghrelin secretion observed with 
norepinephrine treatment (63).  Norepinephrine, the neurotransmitter for the sympathetic nervous 
system, stimulates ghrelin secretion. The other half of the autonomic nervous system is the 
parasympathetic branch which helps manage the rest and digest functions of the body facilitating 
the processing and storage nutrients consumed. The main regulator of this system in the stomach 
is the vagus nerve and its role in ghrelin secretion has been examined. Vagotomised rats showed 
no change in post meal ghrelin suppression (42). However, the increase in ghrelin secretion 
during a fasted state was lost in these animals, indicating a role for stimulating ghrelin secretion 
in a fasted state (42). Another study has confirmed these findings and shown that stimulation of 
the vagus nerve to increase fasting ghrelin levels may be activated by thyrotropin releasing 
hormone in the central nervous system which is known to regulate the secretion of other 
metabolic hormones (75). Intracisternal injection of the thyrotropin releasing hormone analogue 
 
18 
increased peripheral plasma ghrelin and feeding in mice through activation of vagus nerve in the 
dorsal vagal complex (75). The increases in peripheral ghrelin secretion were lost when atropine, 
a cholinergic inhibitor, was delivered or a vagotomy was performed (75). This confirms the 
increase in ghrelin secretion is signaled through the parasympathetic nervous system, specifically 
the vagus nerve. Other studies have reinforced the involvement of branches of the autonomic 
nervous system. In one study, pharmacological agonists and antagonists and vagotomy 
confirmed that activation of adrenergic receptors increased ghrelin secretion, and vagotomy 
removed the stimulation of ghrelin secretion initially but, stimulation was increased 7 days after 
vagotomy (76). All of these findings together reinforce the complex involvement of the nervous 
system in regulation of appetite regulating hormones in the GI tract. The portion of the nervous 
system that stimulates the GI tract is known as the enteric nervous system. With the increased 
frequency of vagotomies over recent years, enteric control in the GI tract has been examined and 
has been seen to be capable of sensory and stimulatory effects independent of the central nervous 
system (77). The enteric nervous system has thus been called the second brain as it can send and 
receive stimuli independent of the central nervous system (78). The role of the enteric nervous 
system in controlling gut motility and secretions in the GI tract may also be expanded to 
endocrine hormone release and be primary responsible for regulating ghrelin secretion. 
As seen in this section, many different stimuli can regulate the secretion of ghrelin, including 
other metabolic hormones. These stimuli in the digestive system end up signaling not just the 
regulation of one but multiple hormones and systems. 
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1.3.4.4 Macronutrient Suppression of Ghrelin Release 
Just as fasting can stimulate the secretion of ghrelin, the ingestion of macronutrients has been 
shown to have an inhibitory effect on ghrelin secretion. The ingestion of actual nutrients is 
required to decrease ghrelin secretion, noncaloric water meals had no decrease in ghrelin (33).  
The previous study confirms that nutrient sensing is central to the inhibitory effect on ghrelin 
secretion. This was demonstrated again by the observation that rats receiving a glucose infusion 
with a pyloric clamp blocking entry to the duodenum showed no postprandial ghrelin drop 
compared to their unclamped counterparts (79). A study by Callahan et. al examined the effect of 
caloric content on postprandial ghrelin drops and found that higher calorie meals caused greater 
decline in blood ghrelin levels and longer feelings of fullness (80). The type of macronutrient 
also influenced ghrelin suppression. Carbohydrates and proteins had a stronger suppression of 
ghrelin secretion, while lipids had a smaller effect. It was also found that carbohydrates had a 
rebound effect where ghrelin levels rose back to higher plasma concentrations quicker. Protein 
meals not only triggered the largest decrease in ghrelin secretion, but they also led to a more 
prolonged suppression (81). This finding was further examined, and it was shown that when 
specific amino acids were ingested they had varying levels of ghrelin and appetite suppression 
(82). The amino acids containing sulfur groups were found to have the largest effect on both 
appetite and ghrelin (82). This led us to propose that these sulfur-containing amino acids are 
being metabolized into a molecule(s) signaling the suppression of appetite and ghrelin secretion. 
The molecule we believe is responsible for this is H2S. 
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1.4 H2S a Gasotransmitter 
H2S has long been thought of as a toxic gas (83). While colourless, it gives off a pungent smell, 
is highly flammable and can cause serious harm to humans in high concentrations. Despite this, 
it is produced by many tissues in our bodies. More recently it has been established as a 
gasotransmitter, a gaseous biological signaling molecule, responsible for regulatory functions in 
multiple systems. The previous section discussed a metabolic hormone, ghrelin, that is important 
for weight management and metabolic health. Our group as well as other studies have shown that 
H2S can regulate other metabolic hormones such as insulin and GLP-1 (84,85). Our study was 
conducted to investigate if H2S may affect ghrelin secretion. 
 
1.4.1 Direct Effects of H2S on Cellular Proteins 
H2S is a small gaseous molecule that can freely move through cellular membranes and react with 
proteins through a process called sulfhydration. Sulfhydration involves H2S reacting with a free 
sulfhydryl (-SH) group and forming a persulfide (-SSH) group, therefore it can interact with any 
protein that contains a S atom. Sulfhydration will generally increase and maintain the active 
configuration of the target protein (86). Several target proteins will be discussed in the following 
sections. 
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1.4.1.1 KATP Channel Sulfhydration 
Ion channels are a well documented target for sulfhydration by H2S and KATP channels are one of 
the best examples of this. The SUR1 subunit is the target for sulfhydration as it contains a 
cysteine amino acid with a free sulfhydryl group near the opening of channel. H2S can 
sulfhydrate this cysteine forming a persulfide group from the free sulfhydryl which then holds 
the channel in the open configuration (87). The opening of KATP channels by H2S can cause 
vasorelaxation of vascular tissues, cardioprotective properties in the myocardium, inhibition of 
insulin release from β-cells, neuroprotection and decreased leukocyte efficiency. The 
understanding of H2S’s effect in these systems has been examined using a combination of KATP 
channel inhibitors (glibenclamide, gliclazide), H2S donors (NaHS) and endogenous H2S 
producing enzyme inhibitors (PPG) (88–93).  
 
1.4.1.2 cAMP Activation 
Increased production of cAMP by adenyl cyclase has also been investigated as a potential target 
for H2S within cells. Increased cellular cAMP can then activate more PKA through 
phosphorylation and which can in turn regulate the activity of many other cellular processes, 
including increased activation of PI3K and AKT. The increased effects of long term potentiation 
in learning in memory from H2S are attributed to the cAMP/PKA pathway (94,95). Other 
experiments concerning H2S’s effect in the nervous system involved increased neurotransmitter 
release. With the use of an adenyl cyclase inhibitor the increased neurotransmitter release was 
maintained despite decreased production of cAMP (96). This suggests that H2S may directly 
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target PKA or another downstream molecule in this pathway such as PI3K or AKT to elicit the 
increased neurotransmission. 
 
1.4.1.3 PI3K Activation 
Direct sulfhydration of the PI3K enzyme has not yet been confirmed, yet it is currently under 
investigation. H2S has been shown to increase both PI3K and AKT activity in both cardiac and 
neural cells of mice that have suffered a traumatic brain injury (97). This increased signaling was 
accompanied by decreased apoptosis and increased mitochondrial integrity (97). Improved 
cardiac function after an ischemic event has also been shown with the use of H2S donors, which 
is reversed in the presence of PI3K inhibitors (98). PI3K and AKT are intracellular signaling 
molecules that have important roles in signaling cell survival and proliferation (69). As discussed 
previously, the PI3K pathway is involved in the suppression of ghrelin secretion by insulin and 
will be a pathway investigated as part of the manuscript in section 2 (63). 
 
1.4.2 H2S Signaling Effects 
H2S is readily available and actively produced in living systems. This portion of the manuscript 
will discuss the importance of H2S as a signaling molecule and the effects elicited. With a better 
understanding of what H2S can do, new technologies to modify its production and availability 
could be developed to alter those functions. 
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1.4.2.1 H2S in the Endocrine System 
As the hormone ghrelin is the focus of this manuscript, it is important to discuss the effects H2S 
has in the endocrine system. H2S-generating enzymes are found in abundance in cells within the 
pancreatic islets, which led to the investigation of the effects it may have on these endocrine cells 
(99,100). H2S has been shown to inhibit glucose-stimulated insulin secretion from pancreatic β 
cells. This has been examined thoroughly with the use of both in vitro and in vivo experiments. 
The mechanism of insulin suppression is through the activation of KATP channels. This occurs by 
sulfhydration of the sulfhydryl group in KATP channels which maintains activation of the channel 
(87). Our group has recently expanded on the field of how H2S can regulate hormones with a 
study showing that increasing H2S production in the GI tract can increase GLP-1 secretion (85). 
H2S’s effects on the endocrine system are a new and interesting field. This manuscript expands 
the field to introduce how H2S can modify ghrelin secretion. 
 
1.4.2.2 H2S in the Gastrointestinal System 
A majority of H2S is produced in the GI tract by the microbiome (101). Sulfate-reducing bacteria 
in the lumen of the GI tract produce H2S and many cells of the stomach and small intestine 
contain enzymes responsible for H2S production (102). The effects of microbially produced H2S 
include cytoprotection, immune response regulation and regulation of the GI hormone GLP-1 
mentioned previously (85,103). The endogenous effects of H2S can occur from both microbial 
and enzymatic production of H2S as both methods produce H2S in the body. The primary role of 
H2S on the GI tract has been gastric motility. In the gastric smooth muscle cells of guinea pigs 
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H2S has shown a relaxing effect (104). This however may be tissue specific as muscle tone was 
increased when the same group examined the effect of H2S on the gastric fundus (105). Smooth 
muscle relaxation has also been shown in jejunum and colon tissues from both humans and 
rodents, all of these effects appear to be mediated by the sulfhydration of KATP channels (106). 
Sulfhydration of KATP channels by H2S also mediates an anti-inflammatory response in the GI 
tract, helping to reduce the development of gastric lesions (107). Although sulfhydration of KATP 
channels can explain the effects of H2S on the gastric motility, the previously discussed 
stimulation in gastric motility from ghrelin could also be an indirect way in which H2S controls 
gastric motility. 
 
1.4.2.3 H2S in Other Systems 
The enzymes responsible for the endogenous production of H2S are located in many tissues of 
the body, the most well documented being the cardiovascular system. An exciting finding is a 
negative inotropic effect in rat hearts during ischemia and reperfusion injury which could 
potentially translate to cardio protective effects in humans (108,109). Other effects include 
vasodilation of vasculature through the relaxation of smooth muscle cells in a variety of blood 
vessels and the occurrence of hypertension and vasoconstriction in the absence of endogenous 
H2S production (110,111). H2S also has regulatory effects on the proliferation of vascular tissues. 
Of note are the inhibition of growth and apoptotic effects on vascular smooth muscle cells and 
the stimulation of proliferation in the endothelial cells on the vascular tissues (112,113). In the 
nervous system H2S can increase long term potentiation, a form of increased synaptic strength 
associated with increased memory consolidation (114). This process has been studied in rodents 
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and is known to be regulated by the stimulation of NMDA receptors, likely through an increase 
in cAMP production (94). Physiological levels of H2S have been shown to enhance the activity 
of these pathways, although prolonged higher doses of H2S have negative effects on long term 
potentiation (114,115). Anti-inflammatory effects of H2S have been noticed and primarily 
explained by a decreased ability for leukocyte adherence and infiltration into the vascular 
endothelium (89). Other suggested mechanisms are increased expression of genes for heme 
oxygenase, through increased extracellular signal-regulated kinase (ERK) activation, which can 
reduce oxidative stress (116,117). H2S has also been shown to have pro-inflammatory effects, 
and can increase pro-inflammatory cytokine production from monocytes (118). High levels of 
H2S in the blood are seen in conditions such as sepsis and treatment using DL-propargylglycine 
(PPG), an inhibitor of endogenous H2S production, improved survival of mice with sepsis, 
whereas the use of H2S donors exacerbates the condition and increases mortality (119). The liver 
and kidney contain the highest expression of endogenous H2S-producing enzymes leading to the 
study of H2S in these organs. They primarily revolve around vascular tone, increasing the arterial 
buffer capacity in the liver and glomerular filtration rates in the kidney (120,121). Ischemia 
reperfusion injury to both of these tissues can also be partially reduced and reversed by treating 
with H2S donors and from the natural production in these tissues (122–124). All of these effects 
and more are thoroughly reviewed in (103). 
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1.4.3 H2S Production 
The role H2S plays in signaling functions in biological systems is important. This signaling 
process requires that H2S first be produced. This section will discuss the methods of H2S 
production that modify the concentration to appropriately signal different functions in the body. 
 
1.4.3.1 Endogenous Enzymes 
Endogenous H2S-producing enzymes are primarily found within the cytosol of cells. H2S 
produced via enzymes can act on the cell producing H2S or diffuse out of the cell. Cystathionine 
γ-lyase (CSE) and cystathionine β-synthase (CBS) are the enzymes that produce the majority of 
enzymatic H2S. CSE is expressed more in peripheral tissues such as the vasculature, liver and 
stomach, whereas CBS is predominantly expressed in the nervous system. The major metabolites 
of these enzymes are L-cysteine and homocysteine. (125–129). As the stomach produces a 
majority of the ghrelin in the body, it is worth mentioning that CSE is the primary H2S-
producing enzyme in gastric cells and the primary mechanism for production in these cells (130). 
CSE functions by using L-cysteine as a substrate and water and pyridoxal-5-phosphate (P5P) as 
co-substrates to cleave the C-γ-S bond forming H2S, NH3 and pyruvate (103). Other reactions 
utilizing CSE to form H2S use the catalytic cleavage of C-γ-S bonds but are less common in 
gastric cells. CBS will primarily facilitate the production of H2S through the reaction of water 
and L-cysteine to form L-serine and H2S (103). To a lesser degree 3-mercaptopyruvate 
sulfurtransferase (MST) and cysteine aminotransferase (CAT) produce H2S, although they are 
tissue specific (131). These two enzymes work together, first CAT converts cysteine to 3-
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mercaptopyruvate through a transaminase reaction with α-ketobutrate using P5P as a cofactor 
(132). MST will then transfer the sulfhydryl group from 3-mercaptopyruvate, forming pyruvate. 
This reaction accounts for the enzymatic formation of acid-labile sulfur in the mitochondria 
discussed in the next section and can be reduced to release free H2S (103). This enzymatic 
production contributes to the approximately 50µM concentration of H2S in blood (129). Other 
less prominent mechanisms for endogenous H2S production as well as those discussed are further 
reviewed in (103). 
 
Figure 3: Pathways for endogenous H2S production (Adapted from (103)) 
 
 
28 
1.4.3.1.1 Availability of L-Cysteine 
As endogenous H2S in the models we are studying is produced enzymatically using the substrate 
L-cysteine, it is worth mentioning the availability of this substrate. L-cysteine can come from 
dietary sources, although it is considered semi-essential as it can also be made in the body 
through other sources. Endogenous formation of L-cysteine can be obtained through either 
protein degradation or the enzymatic conversion of methionine to L-cysteine (reviewed in (133)). 
This amino acid can then be used as a substrate to produce several products that have important 
functions in our bodies. 
 
1.4.3.1.2 Other Effects of L-Cysteine 
Aside from the capacity for L-cysteine to be enzymatically metabolized into H2S, it can be 
metabolized into other products which may be producing some of the effects seen when using 
this amino acid as a treatment. L-cysteine is the rate limiting substrate in the formation of 
glutathione.  Glutathione is a substrate for glutathione peroxidase which acts to reduce reactive 
oxygen species decreasing oxidative stress in our cells (134). Glutathione peroxidase contains a 
selenol group which acts as a reducing agent for hydrogen peroxide converting it into two 
molecules of water. The now oxidized form of glutathione peroxidase will act as an oxidizing 
agent for two molecules of glutathione forming glutathione disulfide. The second reaction uses 
glutathione as a substrate and allows glutathione peroxidase to reduce more reactive oxygen 
species present in the cell. Another product of L-cysteine metabolism is taurine, which requires 
numerous enzymatic steps. This amino acid has several functions but, also has the ability to 
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reduce oxidative stress (135). Taurine reduces oxidative stress by reducing the production of 
reactive oxygen species produced by the electron transport chain (ETC) in mitochondria. β-
alanine depletes cellular taurine which reduces the function of the ETC and increases superoxide 
production from the mitochondria (136). Complex I and complex III activity is lower in taurine 
deficient cardiomyocytes and produce the majority of superoxides in the ETC (136). Treatment 
of cardiomyocytes with taurine and β-alanine together reduces the superoxide species generated 
by mitochondria and restores complex I and complex III activity (136). The suggested 
mechanism for how taurine improves ETC function is not known but it is suggested that it helps 
mediate the functions of complex I and complex III on the ETC.  
All of these products from L-cysteine including H2S can play a role in reducing cellular 
oxidative stress (137). Therefore, it was important to use an experimental design in our study that 
confirms that H2S the cause of modulation of ghrelin secretion. 
 
1.4.3.2 Microbial Production 
H2S can also be produced by microorganisms in the GI tract. This is in large part due to bacteria 
that reside in our gut microbiome. Hydrogen-consuming bacteria or hydrogenotrophs consume 
nutrients to generate products such as methane, acetyl-CoA and H2S and maintain the 
environment of our microbiome. A specific group of hydrogenotroph known as sulfate-reducing 
bacteria use hydrogen or other organic compounds to reduce a sulfate group forming H2S at 
millimolar concentrations in the lumen (102). The presence of H2S in the lumen has been studied 
and shown to have beneficial effects for repairing ulcers and decreasing inflammation in the GI 
tract mucosa and, as such, is an important molecule for gut health (138). It is also interesting that 
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the majority of H2S stored in our cells and freely available in plasma is lost in germ free mice 
which contain no microbiome (101). Due to this, microbial production of H2S may have a 
substantial role in endogenous H2S signaling. Noteworthy changes in physiology of germ free 
mice include decreased muscular tone in the GI tract, impaired immune function and impaired 
memory formation, as they have been previously discussed in the functions of H2S signaling 
(139–142). 
 
1.4.4 Metabolism and Storage of Endogenous H2S 
Endogenously-produced H2S is involved in signaling. Thus, it is important to understand how 
this gaseous signaling molecule acts in the body. H2S dissolved in cellular cytosol or blood 
plasma is constantly in equilibrium represented by H2S ↔ H+ + HS- ↔ 2H + S2-. The ratio of 
H2S to HS- is about equal in the cytosol of cells whereas in extracellular fluid or plasma the ratio 
of H2S to HS- is about 1:5. This molecule is lipid-permeable and can modify the activity of a 
variety of protein structures through sulfhydration. H2S has a relatively short half-life spanning 
from seconds up to a minute yet is readily available due to production and the ability for it to be 
stored intracellularly (83). 
 
1.4.4.1 Storage of Endogenous H2S 
When not free, H2S can be stored within the cytoplasm of cells as bound sulfane sulfur. This 
classification includes thiosulfates, persulfides, thiosulfonates, polysulfides, polythionates, 
elemental sulfur as well as disulfides which contain a C-S bond adjacent to an unsaturated C. 
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Sulfane sulfur is characterized by covalent bond formation between two sulfur atoms and is 
therefore formed due to the oxidation of H2S. Sulfane sulfur is commonly found bound to 
proteins such as albumin as H2S will react with sulfur containing amino acids modulating the 
function of different intracellular proteins. The most common intracellular reducing agents for 
bound sulfane sulfur are glutathione and cysteine. Due to the relative stability of some of these 
molecules, H2S can be stored in cells and tissues for longer periods than initially predicted. Some 
studies show that tissues containing the enzymatic machinery to produce H2S generally store 
higher amounts of these bound sulfane sulfurs (143). Acid-labile sulfur is another intracellular 
store of H2S within the mitochondria of cells. This store of H2S is bound to iron containing 
enzymes through the S group of H2S and is released under acidic conditions (144) 
 
Figure 4: Sulfane sulfur molecules (103) 
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1.4.4.2 Elimination of Endogenous H2S 
Having stores of this bioactive molecule is important for signaling, although in higher 
concentrations it can become cytotoxic, and so removal of H2S from the body is an important 
process. Scavenging of H2S can occur with methemoglobin, hemoglobin by the ferric iron in the 
heme group or by reactions with sulfur atoms in disulfide containing molecules (145,146).  
 
 
The catabolism of H2S into thiosulfate by the enzymes ethylmalonic encephalopathy protein 1 
and sulfur quinone oxidoreductase can occur (147).  This thiosulfate is further oxidized to 
sulfides/sulfates. Oxidation of sulfites to sulfates occurs readily by sulphate oxidase and 
thiosulfates in urine are a general biomarker for endogenous H2S production (148). Methylation 
is a less common and very slow method of H2S elimination (149). H2S can also be exhaled 
through the lungs and has been measured in both breath and as free sulphates in flatulence (150). 
Figure 5: Scavenging of H2S by ferric heme groups 
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Figure 6: Oxidation of sulfites in the kidney 
 
1.4.5 Hypothesis and Objectives 
Ghrelin is a hormone with metabolic functions that is suppressed for a longer duration after 
meals high in protein. Sulfur containing amino acids that make up this protein have a greater 
suppression of ghrelin and appetite compared to other amino acids. Sulfur containing amino 
acids can be metabolized into H2S, a gasotransmitter that can regulate the secretion of other 
hormones such as insulin and GLP-1. We hypothesize that H2S can directly suppress ghrelin 
secretion, and that this will lead to a decrease in appetite.  
This will first be examined via direct treatment of H2S donor to primary gastric culture. Second, 
we confirmed the presence of endogenous H2S producing enzyme in our cell model and tested 
the effect of inhibiting this enzymes production of H2S. Third, we looked at the AKT signaling 
pathway to explore the cellular mechanism thought to be involved with ghrelin secretion. 
Finally, we conducted an in vivo experiment injecting H2S donors to examine the post-prandial 
ghrelin response and determine if that modifies appetite. The following chapter is a submitted 
manuscript that contains experiments completed in this study. 
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Abstract: Ghrelin is a stomach-derived hormone that regulates several metabolic functions 
including growth hormone release, appetite, adiposity, and gastric motility. Nutrients, the 
autonomic nervous system, and other metabolic hormones have all been implicated in the 
regulation of ghrelin secretion. Despite this, ongoing efforts to develop modulators of ghrelin 
secretion in human diseases are still underway. Hydrogen sulfide (H2S) is a gaseous signaling 
molecule that is produced both endogenously in many tissues and by the gut microbiome.  H2S 
has established roles in cardiovascular and immune health, however more recently H2S has been 
implicated in the regulation of metabolic hormone secretion. We hypothesized that H2S is able to 
directly regulate ghrelin secretion and in turn, regulate appetite. We first demonstrated that 
GYY4137 (an H2S donor molecule) directly suppresses ghrelin secretion in rat primary gastric 
culture, in part through the activation of the protein kinase B (AKT) pathway. We then 
demonstrated the colocalization of ghrelin positive gastric cells with the H2S producing enzyme 
cystathionine-γ-lyase (CSE). While GYY4137 suppressed ghrelin secretion, inhibition of CSE 
caused a stimulation in ghrelin secretion in primary gastric culture. In mice, GYY4137 treatment 
prolonged the post-prandial drop of circulating ghrelin and caused reduced food consumption up 
to 4 hours after treatment. These results demonstrate for the first time a role for H2S in the 
regulation of ghrelin and appetite. Modulating H2S levels may be a novel approach to regulate 
ghrelin secretion in the treatment of metabolic diseases.  
 
Keywords: ghrelin, gastrointestinal tract, cell biology, hormone secretion 
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2.1 Introduction 
Ghrelin is a stomach-derived hormone that has metabolic functions throughout the body 
primarily in energy metabolism (7). Ghrelin has been shown to stimulate appetite, stimulate 
growth hormone secretion, promote adiposity and stimulate gut motility (151). As ghrelin plays 
many important roles in metabolism, understanding how this hormone is regulated is of key 
importance in metabolic health and disease. It is well documented that plasma ghrelin levels are 
highest prior to food consumption and are suppressed post-prandially. Accordingly, the circadian 
rhythm of circulating ghrelin fluctuates around meal times, suggesting that ghrelin plays an 
important role in meal cues and post-meal metabolism. There are several pathways involved in 
regulating ghrelin secretion. The type of macronutrient consumed will yield different levels and 
duration of ghrelin suppression with proteins and fats manifesting the longest suppression 
(81,82). The autonomic nervous system has also been implicated in regulating ghrelin secretion 
(63,76). In addition, our research and others has implicated metabolic hormones, including 
insulin and GLP-1 in the regulation of ghrelin (63,70).  
The gasotransmitter hydrogen sulfide (H2S) may have a role in the regulation of ghrelin 
secretion. H2S is an endogenously produced (through several enzymatic pathways) gaseous 
signalling molecule. Research on H2S has largely focused on its cardiovascular effects through 
vascular tone (103), with most studies indicating that H2S is a vasodilator with cardioprotective, 
anti-apoptotic, and anti-inflammatory effects, reviewed in (152). Interestingly, several groups 
have demonstrated a role for H2S in the regulation of insulin secretion, reviewed in (153). In 
endocrine beta cells, H2S has been shown to modulate a variety of ion channels and cellular 
kinases (153). Recently, our group demonstrated a role for H2S in the stimulation of the gastric 
hormone glucagon like peptide 1 (GLP-1). However, the role H2S plays on other metabolic 
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hormones, including ghrelin, remains to be determined.  When examining the production of H2S 
from tissues in mice, the stomach was found to both express the H2S-producing enzyme 
cystathionine-γ-lyase (CSE) and produce detectable levels of this gas (126). Since H2S is 
produced in the stomach (the site of 70-80% of ghrelin production (14)), and is already known to 
regulate other gastric hormones (85,99), we hypothesized that H2S would play a role in the 
regulation of gastric ghrelin. We investigated this hypothesis through a combination of cell and 
animal-based methods. In vitro, using primary rat stomach culture, we tested the effect of H2S 
donors and CSE inhibitors on ghrelin secretion and cell signalling. In vivo, we examined the 
effect of these compounds on post-prandial ghrelin suppression and appetite in mice. 
 
2.2 Material and Methods 
2.2.1  Animals 
  Experiments were performed following the guidelines outlined by the Canadian Council 
on Animal Care guide to the Care and Use of Experimental Animals (CCAC, Ottawa, ON: Vol. 
1, 2nd edition, 1993: Vol. 2, 1984) (154). Animal Protocols were approved by the Laurentian 
University Animal Care Committee. Pregnant female Sprague Dawley rats as well as male and 
female wild-type C57BL/6 mice aged 7-8 weeks were purchased from Charles River 
Laboratories (St. Constant, Quebec). The dams and pups were housed together until pups were 
sacrificed on postnatal day 8 for primary culture preparation. The mice were all singly housed in 
standard cages. All rodents were maintained on a 12-hour light/dark cycle in the Paul Field 
Animal Care Facility at Laurentian University. 
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2.2.2 Primary culture preparation 
 All cell culture media and reagents, unless otherwise stated, were obtained from Sigma 
Aldrich (Oakville, ON, Canada). Primary cell culture was prepared from male and female rat 
stomachs postnatal day 8 as indicated in (63). Briefly, stomachs from each litter were extracted, 
rinsed and enzymatically digested twice with collagenase. The final pellet was resuspended in 
10ml of culture media (low glucose DMEM, 10% fetal bovine serum (FBS), 1% 
Streptomycin/Penicillin (SP)). Cells were plated in 6 or 12 well culture plates for ghrelin 
secretion, western blotting, or immunocytochemistry as indicated below. 
2.2.3 Ghrelin secretion experiments 
 Secretion experiments were conducted using rat stomach primary culture seeded into 6-
well culture plates (2 000 000 cells per well). 24 hours after initial plating the media was 
removed and replaced using a culture media containing 50 µM octanoic acid. After an additional 
24 hours, cells were washed with wash buffer then incubated at 37℃ for 4 hours with treatments 
dissolved in 2 ml secretion media (low glucose DMEM 0.5% FBS 1% SP). The treatments 
(Cayman Chemicals, Ann Armor, MI): H2S donor GYY4137, which releases H2S via hydrolysis 
reactions in solution, CSE inhibitor DL-Propargyl Glycine (PPG) or phosphoinositide 3 kinase 
(PI3K) inhibitor LY294002 were dissolved in DMSO. Media with vehicle (DMSO) served as a 
control for baseline secretion and forskolin (which increases intracellular cAMP) was used as a 
positive control for acylated ghrelin secretion. Following the 4 hour incubation, the media was 
collected and spun down at 1000 x g for 5 minutes to remove floating cell debris. The 
supernatant was acidified using trifluoroacetic acid (TFA) to a final concentration of 0.1% and 
stored at -20 ℃ to prevent protease activity and loss of acylated ghrelin. The cell lysates were 
collected off the plate using a cell scraper in 500 µL of an acidic lysis buffer (1M HCl, 1% TFA 
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and 50 mM NaCl) and sonicated for 10 seconds on ice (155). The lysate was spun down at 13 
000 x g at 4 ℃. The supernatant was separated from cell debris and stored at -20 ℃. The media 
and lysates were subjected to hydrophobic reverse phase resin chromatography (C-18 SepPak 
cartridges, Waters) according to manufacturer’s instructions and eluted in 5 ml of 80% 
isopropanol in water containing 0.1% TFA. Samples were then dried in a vacuum concentrator. 
These dried samples were stored at -20 ℃ until analysis using a commercial acylated ghrelin 
enzyme immunoassay kit described below. Cell viability was determined under similar 
experimental conditions using the neutral red uptake assay described in (156).  
2.2.4 Western blot 
 Primary stomach cells were seeded into 6-well culture plates (2 000 000 cells per well) 
and received treatments after 48 hours as indicated above. On the day of treatment, cells were 
washed with wash buffer and treated with secretion media alone or secretion media 
containing100 μM GYY4137 for 15 minutes at 37 oC, 5% CO2.  Each well received 100 μl of 
Cytobuster cell lysis buffer (EMD Biosciences, Gibbstown, NJ) supplemented with protease and 
phosphatase inhibitor cocktails (Complete Mini/Phospho-Stop; Roche Applied Science, Guelph, 
Ontario, Canada) and cells were collected, sonicated on ice (10 seconds, Power 4), and 
centrifuged (5 minutes, 13 000 x g, 4 oC). Protein concentration was measured using the 
Bradford protein methods and the expression levels of phosphorylated AKT and total AKT were 
analyzed by Western blotting. 20 μg of protein was loaded per lane on 4-12% acrylamide sodium 
dodecyl sulphate-polyacrylamide gels and run at 180 V. The protein was then transferred for 1.5 
h at 200 V onto a polyvinylidene fluoride membrane, blocked in 5% w/v milk powder and 0.1% 
Tween 20 TRIS buffered saline (TBST) for 45-minutes, then incubated in primary antibodies 
(see table 1) in TBST containing 5% BSA overnight. After 3 x 5 minute washes in TBST, the 
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membrane was incubated with a horseradish peroxidase-conjugated secondary antibody at a 
concentration of 1:2000 for 1 hour at room temperature. Signal was developed by exposing the 
membrane to Luminata Forte Western HRP Substrate (Millipore Corporation, Millerica, Ma) for 
two minutes. Chemiluminescence signal was recorded using a BioRad Chemidoc XRS 
documentation apparatus and analyzed using QuantityOne program. Densitometry was used to 
analyze band intensity to compare phosphorylated AKT and total AKT protein expression 
between treatments.  
2.2.5 Immunocytochemistry and Immunohistochemistry 
 Primary stomach culture cells (1ml of culture media) were plated at a concentration of 
1000000 cells per mL on sterile glass cover slips in a 12 well cell culture dish. After 24 hours in 
culture, wells were washed 3 x 5 minutes with TBS containing 4% paraformaldehyde (PFA) for 
20 minutes at room temperature. Cells were washed again 3 x 5 minutes with TBS. Cells were 
then treated with 500 μl per well of a permeabilizing/blocking solution (5% normal donkey 
serum (NDS), 0.1% Triton X-100 in TBS) for 30 minutes.  
 Paraffinized fundus tissue sections of mouse C57 stomach were purchased from Zyagen. 
Tissue sections were deparaffinized as indicated in (157) excluding the microwave antigen 
retrieval.  
 Primary antibodies for ghrelin and CSE were added to the cover slips and tissue sections 
and incubated overnight in blocking solution at 4 ℃ as indicated in table 1. Cells and tissue were 
washed three times in TBS and then incubated in secondary antibodies (Table 1) in blocking 
buffer for 45 minutes in the dark. After 3 x 5 minute washes in TBS, the cover slip was placed 
cell-side down into Fluoroshield Mounting Medium with DAPI (Abcam, Toronto, Canada) and 
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fixed using clear nail polish. The cells were observed in a dark room using an inverted Zeiss 
Axioplan fluorescent microscope and images were captured using the Zeiss AxioVision software 
(Zeiss, Oberkochen, Germany). 
2.2.6 In vivo H2S experiments 
 Separate experiments were conducted for the H2S inhibitor (PPG) and donor (GYY4137) 
studies. Following a week-long acclimation period in the animal care facility, male and female 
mice were divided into control and treatment groups. All animals were fasted overnight (16 
hours) to ensure high basal ghrelin levels. For CSE inhibitor experiments, PPG (30 mg/kg body 
weight) or saline was injected intraperitoneally (IP) 16 hours prior to glucose delivery, while the 
H2S donor GYY4137 (30 mg/kg body weight) or saline was IP-injected 30 minutes prior to 
glucose delivery. Animals then received an oral glucose gavage (2 g/kg body weight in water) to 
elicit a nutrient-induced drop in circulating ghrelin (80). A small prick was made in the 
saphenous vein of the animal and blood was collected into EDTA coated capillary tubes for 
ghrelin measurements at 0, 30 and 60 minute timepoints after the oral glucose gavage. After 60 
minute blood collection, pre-weighed food was returned and consumption was measured at 1, 2, 
3, 4, and 24 hour timepoints. Blood samples were stored on ice and centrifuged at 6000 x g, 4 ℃ 
for 6 minutes. 20 µl of plasma was used in an enzyme immunoassay kit for acylated ghrelin. 
2.2.7 Ghrelin Assays 
 Ghrelin levels in cell culture and plasma samples were determined using an acylated 
ghrelin enzyme immunoassay kit (Cayman Chemical, Ann Arbor MI) as per manufacturer’s 
guidelines. Dried media and lysate samples were resuspended in immunoassay buffer 
immediately before assay. Ghrelin levels were determined for entire media and cell lysate from 
each sample. Results for various treatments were presented as a percent secretion 
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(media/media+cell) relative to untreated control. Acylated ghrelin was analyzed using 20µl of 
plasma diluted in assay buffer. 
2.2.8 Data Analysis 
 All data are expressed as mean ± SEM. Studies comparing 2 groups were analyzed by 
student’s t-test. Studies with multiple doses of the same treatment were analyzed by one-way 
ANOVA, followed by a Bonferroni post hoc test. Studies with 2 independent variables were 
analyzed by two-way ANOVA, followed by a Bonferroni post hoc test at individual time points 
where applicable. P <0.05 was considered significant. 
 
2.3 Results 
The H2S donor GYY4137 suppresses ghrelin secretion in vitro 
 To determine the direct effect of H2S on ghrelin secretion, a slow releasing H2S donor, 
GYY4137, or control media was applied to a rat stomach primary culture for 4 hours. The mean 
total of secreted ghrelin from primary culture controls was 146.9 ± 15.58 pg/ml. Overall, 
GYY4137 decreased ghrelin secretion (P <0.05 overall one-way ANOVA), with the highest dose 
(500 µM) causing the largest decrease (0.47 ± 0.07 fold of control Fig. 7A). Cell viability 
examined by the neutral red assay was not affected by GYY4137 treatments (Fig. 7B). 
 As previous studies have demonstrated a role for the AKT pathway in ghrelin 
suppression (63), we next investigated AKT phosphorylation in rat stomach primary cultures 
treated with GYY4137. GYY4137 caused a significant increase in the levels of 
phosphorylated/total AKT compared to control (P <0.01, Fig. 7C). To determine if the AKT 
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pathway is required for GYY4137 mediated ghrelin suppression, we co-incubated cells with 
GYY4137 and the PI3K inhibitor LY294002. In these experiments, the effect of GYY4137 was 
not completely blocked by LY294002 (no statistical interaction); however, the significant 
suppression of ghrelin secretion normally seen with GYY4137 alone is lost in the presence of 0.1 
µM LY294002 (P <0.01 in post hoc analysis, Fig. 7D). 
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Figure 7: H2S suppresses ghrelin secretion in gastric primary culture. 
Percent acyl ghrelin secretion (A) and neutral red absorbance (B) relative to control was 
examined after 4-hour treatments with GYY4137. Phosphorylated AKT and total AKT were 
analyzed using a Western blot in cells treated for 15 minutes with GYY4137(C). Percent acyl 
ghrelin secretion relative to control was examined after 4-hour treatments with GYY4137 and/or 
the PI3K inhibitor LY294002 (D).  n = 3-6; * = P < 0.05 vs. control cells, ** = P < 0.01 vs. 
control cells.  
 
Endogenous H2S regulates Ghrelin in vitro  
 Since exogenous H2S caused a suppression in ghrelin secretion, we next examined the 
role of endogenous H2S in ghrelin regulation. To ensure the rat stomach primary culture was a 
suitable model to study endogenous H2S production, we examined the protein expression of the 
H2S-synthesizing enzyme CSE using fluorescent immunocytochemistry. CSE was expressed 
throughout the primary culture preparation (Fig. 8A). As such, all ghrelin positive cells in the 
primary culture preparation also co-expressed CSE (Fig. 8A). We then examined mouse stomach 
fundus using immunohistochemistry to examine abundance and distribution of ghrelin and CSE 
expressing cells (Fig. 8B). Cellular expression of cells producing ghrelin, CSE or co-localized 
expression were determined from a count of 100 cells (Fig. 8D). To ensure the fluorescent signal 
for CSE was specific to this enzyme, we completed a western blot of total cell lysate using the 
anti CSE antibody and detected a signal band at 44 kDa (corresponding to the correct molecular 
weight of CSE, Fig. 8C). 
 As we observed a high level of CSE signal in the primary culture preparation, we next 
determined the effect of inhibiting this enzyme on ghrelin secretion. Cells incubated with the 
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CSE inhibitor PPG had an overall increase in ghrelin secretion (P <0.001 one-way ANOVA), 
with the highest dose (10 mM) being 1.28 ± 0.06 fold of control (Fig. 8E) without any effect on 
cell viability as shown in the neutral red assay (Fig. 8F). 
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Figure 8: Inhibition of CSE stimulates ghrelin secretion. 
Primary stomach culture and stomach fundus tissue were examined by fluorescent 
immunocytochemistry/immunohistochemistry for ghrelin (green), CSE (red), and nuclei (blue, in 
merge)(A, B). CSE MW was confirmed by western blot in primary stomach culture (C). Cells 
expressing ghrelin, CSE or both were counted in a 100 cell preparation to determine abundance 
and location within the fundus (D). Acylated ghrelin secretion from primary stomach culture was 
examined after 4-hour treatments with the CSE inhibitor PPG (E). Cell viability was examined 
under similar conditions (F). n = 6-9; *** = P < 0.001 vs. control cells.  
In vivo effects of H2S on post-prandial ghrelin levels 
 All animal experiments were completed using both male and female mice. Since no 
statistically significant difference was observed between sex in all parameters investigated, we 
combined the male and female data sets. The mean basal plasma ghrelin levels of mice was 
77.24 ± 4.35 pg/ml in the control group and 87.88 ± 8.23 pg/ml in the treatment group. To 
determine if the reduction of ghrelin secretion seen in the primary culture with the H2S donor 
GYY4137 would translate to the vivo model, mice were given an IP injection containing either 
saline or 30 mg/kg GYY4137 prior to the nutrient gavage. While no difference in circulating 
ghrelin levels were observed at time 0 and 30 minutes between treatment and controls, 
GYY4137 significantly prolonged the post-prandial ghrelin suppression at 60 minutes with 0.83 
± 0.07 fold suppression for control (Male 0.90 ± 0.12, Female 0.75 ± 0.06) and 0.59 ± 0.07 fold 
suppression for treatment (Male 0.55 ± 0.07, Female 0.62 ± 0.13) (Fig. 9A, P < 0.05).  
 To determine if the increase in ghrelin secretion seen in our primary culture with the CSE 
inhibitor would translate to an in vivo model, mice were given an IP injection containing either 
saline or 30 mg/kg PPG prior to the nutrient gavage. While a trend of increased ghrelin levels 
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was seen 60 minutes after glucose in treated animals (Fig. 9B), this was not statistically 
significant (P > 0.05 two-way ANOVA treatment effect).  
 
Figure 9: In vivo effects of H2S on post-prandial ghrelin suppression 
Plasma acyl ghrelin was measured in mice receiving single injection of the H2S donor GYY4137 
(A) or the CSE inhibitor PPG (B) at 0, 30 and 60 minutes after and given an oral glucose gavage. 
n = 14 – 15 per group; * = P < 0.05 vs. control animals. 
In vivo effects of H2S on food consumption 
 Since GYY4137 prolonged post-prandial ghrelin suppression in mice, we next evaluated 
its impact on food consumption.  GYY4137 caused a significant reduction in cumulative food 
consumption (P<0.05 for treatment effect) with the 4 hour time point having the greatest 
difference at 1.04 ± 0.09 g in control (Male 1.02 ± 0.08, Female 1.04 ± 0.18) vs 0.77 ± 0.06 g in 
treatment (Male 0.85 ± 0.09, Female 0.69 ± 0.07) (Fig. 10A, P<0.01 post hoc test). When total 
food consumed was examined at the 24 hour mark, no difference in food consumption was 
observed (Fig. 10B). Similar to the lack of effect observed with PPG for ghrelin secretion, no 
effect was observed with PPG for food consumption (data not shown).  
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Figure 10: H2S reduces short term food consumption in mice. 
Cumulative food consumption was examined in fasted mice after a single i.p. injection of the 
H2S donor GYY4137 up to 4 (A) and 24 hours (B). n = 14 – 15 per group; * = P < 0.05 vs. 
control animals. 
 
2.4 Discussion 
 In this study, we examined the role of H2S in the regulation of ghrelin secretion and 
appetite. This was investigated through a combination of cell and animal-based studies using a 
H2S donor, as well as an inhibitor of endogenous H2S production.  
 Using primary stomach cultures, we determined that the H2S donor GYY4137 causes a 
suppression in ghrelin secretion and an increase in the phosphorylation of AKT. We determined 
the use of the slow releasing H2S donor GYY4137 would be the most effective H2S donor to use 
as it can maintain steady H2S concentrations for the length of both our primary culture and in 
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vivo experiments (158). H2S readily diffuses from solution at room temperature and quick 
releasing H2S donors would not be able to maintain media H2S concentrations for our primary 
culture experiment duration (103). Our finding of increased AKT activation with reduced ghrelin 
secretion is in agreement with previous rat primary culture studies delineating the mechanism of 
insulin-induced ghrelin suppression (63). We recognize the lower total AKT levels in our 
GYY4137 treatments appear to be contribute to the increased ratio of phosphorylated AKT, 
although other studies have shown that AKT degradation occurs during vascular endothelial 
growth factor (VEGF) inhibition (159). GYY4137 may increase the degradation of AKT as it 
increases nitric oxide production which decreases VEGF release (160). The precise mechanism 
of how AKT phosphorylation is triggered by H2S is not clear. Nevertheless, other groups have 
demonstrated the ability of H2S to increase phosphorylated AKT levels in cancer cells (161) and 
endothelial cells (112). The latter being a required pathway for the proangiogenic effects of H2S. 
When we co-incubated the primary culture with the H2S donor and the kinase inhibitor 
LY294002, a partial loss of ghrelin suppression was observed. However, our analysis did not 
demonstrate significant interaction for LY294002, which suggests that pathways other than PI3K 
AKT may be involved in H2S mediated ghrelin suppression.  
 Endogenous H2S production from rat stomach primary culture was measured using a 
methylene blue experiment (data not shown). Measurable H2S was unable to be quantified in our 
primary stomach culture as the quantity of cells produced from this method are not sufficient to 
measure H2S production. This is due to the comparatively low levels of expression of H2S 
producing enzymes in the stomach as opposed to the liver (130). 
 When examined in vivo, GYY4137 also caused lower levels of circulating ghrelin 60-
minutes post-prandial. This prolonged drop is important since in humans ghrelin levels normally 
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rise 1-hour after oral glucose challenge (162). The ability of the H2S donor to keep post-prandial 
ghrelin levels lower may lead to reduced feeding. Indeed, this delayed rise in ghrelin coincided 
with less food consumption over the next 4 hours. It should also be mentioned that while we 
predict that reduced ghrelin levels are responsible for the reduced food consumption in this 
treatment, additional experiments using ghrelin deficient mice would clarify this. This gap in 
food consumption between treatment and control eventually closed, as there was no difference in 
total food consumed at the 24 hour time point. Future work examining daily delivery H2S donors 
will clarify whether prolonged food consumption effects are possible.  
 
 CSE and cystathionine-β-synthase (CBS) are the predominant H2S producing enzymes in 
the body, although CBS is predominantly expressed in the central nervous system (125,163). As 
previous work demonstrated that inhibition of CSE reduced nearly all gastric H2S production 
(126), we focused our examination of endogenous H2S on CSE.  We found CSE 
immunofluorescence throughout the stomach primary culture preparation. Expression was not 
restricted to ghrelin producing cells, however all ghrelin producing cells were positive for CSE. 
This suggests that the stomach possesses the ability to generate H2S, and that ghrelin producing 
cells may be regulated by this gas in both an autocrine and paracrine manner. Furthermore, our 
detection of CSE enzyme in the stomach is in agreement with previous studies. Early work on 
CSE demonstrated that while the liver and kidney have the highest levels of CSE expression and 
activity, the stomach and intestine were the only other organs with detectable levels (130). As the 
H2S donor treatments suppressed ghrelin, we predicted the inhibition of H2S production would 
increase ghrelin. Indeed, when CSE was inhibited with PPG, we observed the expected increase 
in ghrelin secretion in vitro. Surprisingly, while we did see a trend towards increased 60 minute 
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rebound ghrelin levels in the PPG injected mice, this did not reach significance. It is possible that 
sampling the animals at 60 minutes to catch the post-prandial ghrelin rebound was insufficient, 
and that longer time course studies would give a clearer picture. Future work in larger animals 
(rats) will enable additional blood sampling to resolve this. Alternatively, some recent work has 
implicated the other predominant H2S producing enzyme, CBS, in the stomach (164). An 
examination of the effects of CBS inhibitors on ghrelin levels would clarify the potential role of 
this enzyme in ghrelin regulation.  
 In this proof of concept study we investigated the role of both exogenous and endogenous 
H2S in ghrelin regulation and physiology. Together these findings support the possibility that 
H2S plays a suppressive role in ghrelin regulation. Future work should investigate if repeated 
H2S delivery can mediate a sustained reduction in appetite. This could be done via chronic 
delivery of H2S donors or diets enriched in precursors for endogenous H2S production including 
cysteine and methionine. Another approach to increasing circulating H2S may be through 
enhancing microbial H2S production. Indeed, microbes are responsible for 50-80% of circulating 
H2S (101). Our group has demonstrated that sulfur-containing prebiotics are able to enrich 
Desulfovibrio piger and elevate H2S levels in the colon of mice, leading to increased GLP-1 
secretion (85). While in the latter study ghrelin levels were not measured, it is possible that this 
colonic source of H2S could have a significant impact on ghrelin cells.  
 
 In conclusion, this study demonstrates for the first time, a role for H2S in the regulation of 
ghrelin and appetite in rodents. Future work will continue to elucidate the mechanisms of H2S 
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action on ghrelin producing cells as well as the ability of H2S to reduce appetite and stimulate 
weight loss through the ghrelin system.  
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3 Extended Discussion 
3.1 Potential Applications of H2S for Appetite Control 
As seen in this study, the use of a H2S donor can both decrease ghrelin secretion in vitro and 
delay post-prandial ghrelin secretion while reducing appetite in a mouse model. These findings 
support the idea that increased cellular H2S production, or the supplementation of H2S, may lead 
to prolonged appetite suppression. A study from our group using chondroitin sulfate, a prebiotic 
that can promote the growth of sulfate-reducing bacteria, and colonic H2S production also 
showed an increased secretion of the appetite suppressing hormone GLP-1. This was 
accompanied by a decreased food consumption in obese mice given the prebiotic during the last 
9 days of the appetite study (85). While we did not measure ghrelin levels in that study, these 
findings help support the idea that H2S, whether of endogenous (through microbial or tissue-
based production), or exogenous (through H2S donors) sources, helps signal feelings of fullness 
and could promote sustained weight loss in obese individuals. In the present thesis, only short-
term refeeding was examined. Indeed, our single injection did not yield sustained 24-hour 
reduced food consumption. Of interest would be a long-term appetite study where H2S donors 
are given daily to monitor if appetite reduction can be sustained past the 24-hour period. 
While the use of H2S donors to modify ghrelin secretion is preclinical, there are some new 
therapies being tested containing H2S releasing molecules. Nonsteroidal anti-inflammatory drugs 
(NSAID) are commonly used for chronic pain and have recently been shown to help treat 
specific cancers, although a common side effect of the drug is GI damage, including gastric 
lesions (165). A drug called ATB-346 was developed which combines a NSAID (Naproxen) 
with a H2S donor. This compound is currently in phase 2 clinical trials and when tested not only 
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had greater apoptotic effects in melanoma cells but eliminated the side effect of gastric lesions 
associated with naproxen alone (166,167). Another current strategy that is undergoing clinical 
trials involves safely raising the bioavailable levels of H2S in cardiovascular disease (CVD). It is 
currently known that patients undergoing heart failure have lower levels of H2S, and that there 
are cardiac benefits from this gasotransmitter (108,168). SG1002 is an oral H2S prodrug, and can 
safely raise H2S levels in humans (169). The development of a safe treatments that increase 
bioavailability of this gasotransmitter could be a very effective tool not only in CVD but in other 
pathologies where elevated H2S is desired. It would be interesting to see if the effect of these 
novel H2S drugs on metabolic hormones, and by extension, on body weight and glucose 
metabolism.  
 
3.2 The Effect of H2S on Ghrelin: Future Perspectives 
In this study we demonstrated that the H2S donor GYY4137 suppresses ghrelin secretion causing 
a temporary decrease in food consumption. Although, this is the first step, additional experiments 
will need to be completed to fully implicate H2S in ghrelin regulation and appetite.  
While our data suggests that the AKT pathway is activated via H2S and that plays a role in 
suppressing ghrelin release, additional experiments are required. The inhibitor LY294002 is a 
nonspecific inhibitor of PI3K and will prevent more than just the phosphorylation of AKT (170). 
The use of another PI3K inhibitor such as wortmannin or inhibitors of AKT like triciribine could 
increase the confidence in these results yet other experimental techniques would further 
strengthen this claim. Using a KO animal for the AKT gene would not be viable as the complete 
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KO of the AKT gene is lethal (171). Gene knockdown experiments, specifically transient gene 
knockdown with siRNA would be an effective way to study the involvement of AKT in our 
primary culture model. Unfortunately, the primary stomach cell preparation may not be the best 
cellular model for siRNA experiments as knockdown efficiency is often reduced in primary 
culture (172). Clustered regularly interspaced short palindromic repeat interference (CRISPRi) is 
another gene knockdown technique that could be used if transient knockdown is ineffective. This 
technique has been shown to have a higher knockdown efficiency in primary culture cells than 
transient knockdown (173). Gene knockdown techniques would effectively silence AKT 
expression and determine the AKT pathways involvement in H2S induced ghrelin suppression.  
To fully understand the effect H2S has on ghrelin secretion a cellular mechanism must be 
identified. As mentioned in the introduction, H2S has been shown to increase cAMP and PKA 
activity in cells which could potentially make them the target for sulfhydration as opposed to 
PI3K or AKT (95). To discover what the direct target of H2S is in the signaling of ghrelin 
suppression, a modified biotin switch technique should be applied. An alkylating agent would be 
used to block reactivity of sulfhydryl groups present on proteins. Then the persulfide group will 
react with the added biotin conjugate allowing for measurement of sulfhydration between 
treatment groups (174). These proteins are then isolated and can be identified using a western 
blot to show the direct mechanism for the suppression of ghrelin secretion by H2S in our rat 
stomach primary culture. 
Another point that needs to be addressed when studying the effect of H2S is the multitude of 
targets and the effects it has in vivo that were discussed previously. When injecting a H2S donor 
such as GYY4137 H2S will diffuse into all cells not only the gastric cells that secrete ghrelin. 
Alterations in inflammation and vascular tone can modify the stress response in mice which 
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could potentially manipulate appetite (89,111). H2S can also regulate the secretion of GLP-1 and 
insulin altering the secretion of ghrelin (85,99).  These confounding variables make the primary 
culture experiments conducted alongside the in vivo experiments essential to documenting the 
role that H2S has in the regulation of ghrelin secretion. Aside from H2S donors, the inhibitor PPG 
is not exclusively transported into gastric cells. PPG irreversible binds CSE effectively reducing 
H2S production throughout the body (103). Unwanted effects of using PPG are similar to those 
seen in CSE KO mice (175). The CSE KO mice exhibit increased blood pressure and decreased 
vasorelaxation (110). All these variables will should be considered in future experimental design 
as the proper combination of experimental techniques can ensure the validity of our findings. 
Future in vivo experiments will involve a study in high fat diet induced obese mice. Here, daily 
treatment with H2S or supplementation of precursors of H2S will be given to determine if H2S 
can be used to help reverse an obese state. If that study shows that H2S can reverse an obese state 
in mice, it would be important to research whether providing a prebiotic diet could increase H2S 
production by the microbiome to the extent that it alters ghrelin release. Other future studies 
could include the use of CSE KO mice. The use of these mice would examine whether or not 
enzymatic production of H2S in the stomach is responsible for ghrelin regulation. 
 
4 Conclusion 
H2S is a gasotransmitter that has been examined thoroughly in biological systems and the role in 
the endocrine system is now being investigated. Ghrelin is one of many endocrine hormones that 
is primarily secreted from the stomach and is responsible for appetite stimulation, gut motility 
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and the nutrient metabolism. In our study we demonstrated a direct suppression of ghrelin 
secretion when treating our stomach primary culture with H2S donors. This suppression of 
ghrelin secretion as well as a temporary reduction in appetite was also seen during an in vivo 
experiment examining the effects of H2S donors in a mouse model on ghrelin secretion and 
appetite. Further examining the role H2S has in ghrelin secretion and appetite will be a useful 
tool for learning about how this gasotransmitter can signal the regulation of endocrine hormones, 
and whether or not it can help alter or reverse different diseased states such as obesity. 
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